Laurus Labs share price
NSE: LAURUSLABSBSE: 540222Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,002.50.
- Next results date: the board meets on 29 Oct 2026 to consider: financial results and dividend.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,06,442 Cr171st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 24 Jul 2026
- 97.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 Apr 2026
- 20.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.10%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 24 Jul 2026
- 22.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 24 Jul 2026
- 19.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 Apr 2026
- 0.44
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 18,93,71345.3% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 24 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹2,026 Crup 11.85%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹362 Crup 28.35%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 17.9%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2018, GST replaced excise duty on 1 Jul 2017, and revenue before that day includes the duty.
| ₹ crore | Sep 2024Filed 25 Oct | Dec 2024Filed 24 Jan | Mar 2025Filed 12 Jun | Jun 2025Filed 25 Jul | Sep 2025Filed 23 Jan | Dec 2025Filed 23 Jan | Mar 2026Filed 30 Apr | Jun 2026Filed 24 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,224 | 1,415 | 1,720 | 1,570 | 1,653 | 1,778 | 1,812 | 2,026 |
| Net profit | 20 | 93 | 233 | 162 | 194 | 252 | 282 | 362 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 1.6% | 6.6% | 13.5% | 10.3% | 11.8% | 14.2% | 15.6% | 17.9% |
Business segments
In the year to Mar 2026 the company reports one business segment, Manufacturer of Generics API, Generics FDF, Synthesis and Bio Technology, which carries all its revenue.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Mar 2018: days before it are of the company before the change.PE ratio and valuation history
At or below today's level on 82% of 2,205 trading days since Nov 2017.
At or below today's level on 99% of 1,976 trading days since Nov 2018.
At or below today's level on 99% of 1,976 trading days since Nov 2018.
At or below today's level on 6% of 2,423 trading days since Jan 2017.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +62.0% | +147.7% | −34.7% | 0.2% |
| 3 years | +50.4% | +3.9% | +44.6% | 0.2% |
| 5 years | +22.7% | −2.1% | +25.0% | 0.3% |
Mutual funds holding it
219 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 133 of the 168 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 3
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 13
- AddedAdded. Funds that held more shares than at the end of the month before.
- 89
- CutCut. Funds that held fewer shares than at the end of the month before.
- 79
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 34
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 3
| Fund | |||
|---|---|---|---|
 Mirae Asset Large & Midcap FundMirae Asset Mutual Fund | 88,66,688 | 4.10% | ₹1,755.6 Cr |
| Mirae Asset ELSS Tax Saver FundMirae Asset Mutual Fund | 56,58,404 | 4.55% | ₹1,120.4 Cr |
| Mirae Asset Midcap FundMirae Asset Mutual Fund | 42,53,201 | 4.31% | ₹842.1 Cr |
 UTI Nifty 200 Momentum 30 Index FundUTI Mutual Fund | 26,29,596 | 6.54% | ₹520.7 Cr |
 HSBC Small Cap FundHSBC Mutual Fund | 12,82,134 | 1.37% | ₹253.9 Cr |
 SBI Healthcare Opportunities FundSBI Mutual Fund | 12,00,000 | 4.05% | ₹237.6 Cr |
| Mirae Asset Aggressive Hybrid FundMirae Asset Mutual Fund | 9,89,827 | 2.12% | ₹196.0 Cr |
| Mirae Asset Healthcare FundMirae Asset Mutual Fund | 9,72,748 | 5.51% | ₹192.6 Cr |
 Axis Small Cap FundAxis Mutual Fund | 9,00,000 | 0.58% | ₹178.2 Cr |
 WhiteOak Capital Mid Cap FundWhiteOak Capital Mutual Fund | 8,36,111 | 2.20% | ₹165.6 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Laurus Labs in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Divi's LaboratoriesDIVISLAB | 2,37,594 | 81.2 | 14.2 | 59.0 | +16.3% | +26.8% | 18.4% | 20.8% | 0.34% |
 Torrent PharmaceuticalsTORNTPHARM | 1,72,094 | 78.9 | – | – | +32.9% | +8.9% | 27.3% | 11.4% | 0.84% |
 Zydus LifesciencesZYDUSLIFE | 1,12,658 | 25.0 | 4.2 | 14.8 | +21.1% | −1.3% | 17.7% | 15.9% | 0.09% |
 CiplaCIPLA | 1,08,093 | 32.1 | 3.1 | 20.2 | +1.8% | −37.5% | 10.3% | 11.6% | 0.97% |
 Dr. Reddy's LaboratoriesDRREDDY | 1,02,624 | 31.8 | 2.7 | 20.5 | −0.9% | −43.3% | 9.0% | 6.8% | 0.65% |
 Mankind PharmaMANKIND | 91,390 | 44.6 | 5.6 | 25.4 | +13.8% | +8.2% | 13.4% | 12.8% | 0.00% |
 Aurobindo PharmaAUROPHARMA | 90,432 | 24.4 | 2.4 | 12.5 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
 LupinLUPIN | 88,207 | 16.0 | 3.9 | 9.3 | +28.2% | +49.5% | 27.9% | 28.2% | 0.93% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 8 May 2026 | Interim | ₹1.20 |
| 31 Oct 2025 | Interim | ₹0.80 |
| 9 May 2025 | Interim | ₹0.80 |
| 6 Nov 2024 | Interim | ₹0.40 |
| 8 May 2024 | Interim | ₹0.40 |
| 2 Nov 2023 | Interim | ₹0.40 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
14 Oct · General Updates
14 Oct · General Updates
13 Oct · Analysts
6 Oct · General Updates
Sep 2026
15 Sep · Analysts
Laurus Labs share price by year
Each calendar year to 2025.Laurus Labs share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,108.00 | +83.8% | 1,108.00 | 510.75 |
| 2024 | 602.70 | +40.1% | 602.70 | 370.30 |
| 2023 | 430.20 | +14.6% | 435.45 | 289.75 |
| 2022 | 375.25 | −30.4% | 611.05 | 372.80 |
| 2021 | 538.90 | +52.6% | 708.70 | 341.70 |
| 2020 | 353.15 | +390.8% | 353.75 | 63.19 |
| 2019 | 71.95 | −5.2% | 81.06 | 62.05 |
| 2018 | 75.91 | −30.1% | 112.20 | 68.04 |
| 2017 | 108.58 | +12.9% | 125.68 | 94.55 |
| 2016 | 96.17 | – | 97.25 | 91.04 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,987.50 | 2,009.60 | 1,933.50 | 1,970.00 | 1,958.52 | 18,93,713 | 45.3% |
| 22 Oct 2026 | 1,993.50 | 2,019.80 | 1,956.60 | 2,002.50 | 1,996.59 | 15,38,717 | 41.1% |
| 21 Oct 2026 | 2,052.90 | 2,079.80 | 1,993.40 | 2,012.50 | 2,026.31 | 12,75,844 | 46.8% |
| 19 Oct 2026 | 2,060.10 | 2,089.00 | 2,052.20 | 2,069.00 | 2,068.84 | 11,33,053 | 42.8% |
| 16 Oct 2026 | 2,030.40 | 2,086.00 | 2,028.70 | 2,060.10 | 2,062.54 | 16,06,547 | 50.6% |
| 15 Oct 2026 | 2,025.00 | 2,046.30 | 2,008.00 | 2,018.50 | 2,026.98 | 8,58,713 | 51.2% |
| 14 Oct 2026 | 2,049.00 | 2,057.30 | 2,019.20 | 2,036.90 | 2,036.68 | 13,01,046 | 51.0% |
| 13 Oct 2026 | 2,047.10 | 2,065.00 | 2,007.80 | 2,059.40 | 2,036.15 | 11,41,354 | 41.0% |
| 12 Oct 2026 | 2,044.10 | 2,069.20 | 2,036.10 | 2,069.20 | 2,053.59 | 14,17,097 | 57.4% |
| 9 Oct 2026 | 1,997.90 | 2,048.00 | 1,988.90 | 2,036.60 | 2,022.15 | 13,58,268 | 45.7% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 29 Sep 2020 | Split | 0.2000 | Each share became 5. |
About Laurus Labs
Laurus Labs is a research-led pharmaceutical and biotechnology company. It makes active pharmaceutical ingredients (APIs), the substances in a medicine that act on the body, and finished dosage forms, the tablets and other forms that patients take. It also offers contract development and manufacturing services, known as CDMO, to other drug makers, from early-stage development to commercial production. Its offerings span human and animal health APIs, intermediates, crop science and specialty ingredients for nutrition and cosmetics. The company is listed on the BSE and NSE.
The business is presented in two main divisions. Affordable Medicines combines large-scale API manufacturing with finished dosage form manufacturing. CDMO serves global pharmaceutical and biotechnology partners, and the company also describes a growing bio platform built on fermentation.
The manufacturing network is centred on Visakhapatnam, where the plants cover APIs, drug substances and finished dosage forms. Fermentation capability sits in Bengaluru, development infrastructure in Hyderabad, and cell therapy manufacturing in Mumbai through its associate, ImmunoACT. A formulation facility in Hyderabad belongs to KRKA Pharma, a joint venture in which the company holds 49% and the Slovenian company KRKA d.d. holds the rest. Subsidiaries include Laurus Holdings Limited in the United Kingdom and Laurus Generics Inc. in the USA. The company employs over 8,126 people, including more than 3,134 scientists.
Laurus Labs began as a focused API platform and later added formulations. It was incorporated in 2005.
- Legal name
- Laurus Labs Limited
- NSE symbol
- LAURUSLABS
- BSE code
- 540222
- ISIN
- INE947Q01028
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Dec 2016
- Face value
- ₹2
- CIN
- L24239AP2005PLC047518
- Corporate identity number, the registrar of companies' code for it